No Data
No Data
WuXi Biologics' subsidiary, WuXiBody, presented the latest clinical progress of Epigallocathechin-3-Gallate (EGCG) and Pipemidic Acid at the ESMO Annual Meeting.
Gelonghui, September 15th - Hoyu-B (02256.HK) announced that its subsidiary, Shanghai Hoyu Biomedical Technology Co., Ltd. (Hoyu Biomedical), announced at the 2024 European Oncology Society Annual Meeting the latest clinical data on the safety and efficacy of its independently developed small molecule FGFR4 inhibitor, Epagotinib (ABSK011), in Phase I clinical trials for advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression. The data released in this study showed that the Epagotinib 220mg twice daily (BID) group demonstrated safety and efficacy in combination with immune checkpoint inhibitors.
On August 21, Hu Yu-B (02256.HK) spent 1.543 million Hong Kong dollars to repurchase 0.5 million shares.
Glory Times: On August 21st, Hoyo-B (02256.HK) announced the repurchase of 0.5 million shares for 1.543 million Hong Kong dollars on August 21st.
Wah Yuet Group (02256) spent HKD 0.6049 million to repurchase 0.2 million shares on August 20.
Wah Yuet Group (02256) announced that on August 20, 2024, the company spent 0.6049 million Hong Kong dollars to repurchase...
Wah Yuet Group-B (02256.HK) spent 0.07 million Hong Kong dollars to repurchase 0.023 million shares on August 16th.
On August 16, Heyu-B (02256.HK) announced that it had repurchased 0.023 million shares for HKD 0.07 million.
On August 15th, Wuhu-B (02256.HK) spent 0.593 million Hong Kong dollars to repurchase 0.2 million shares.
Hoya Group (02256.HK) announced on August 15th that it spent HKD 0.593 million to repurchase 0.2 million shares.
HK stocks surged | Hopewell-B (02256) rose more than 7%, the company achieved positive profits for the first time, and the implementation of repurchase demonstrates development confidence.
Wah Yuet Group (02256) rose more than 7%, as of the time of publication, up 7.58%, at HKD 2.98, with a turnover of HKD 6.2696 million.
No Data
No Data